FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4380079079> ?p ?o ?g. }

• W4380079079 abstract "In recent years, the incidence of diabetes mellitus has been increasing annually, and cardiovascular complications secondary to diabetes mellitus have become the leading cause of death in diabetic patients. Considering the high incidence of type 2 diabetes (T2DM) combined with cardiovascular disease (CVD), some new hypoglycemic agents with cardiovascular protective effects have attracted extensive attention. However, the specific role of these regimens in ventricular remodeling remains unknown. The purpose of this network meta-analysis was to compare the effects of sodium glucose cotransporter type 2 inhibitor (SGLT-2i), glucagon-like peptide 1 receptor agonist (GLP-1RA) and dipeptidyl peptidase-4 inhibitor (DPP-4i) on ventricular remodeling in patients with T2DM and/or CVD.Articles published prior to 24 August 2022 were retrieved in four electronic databases: the Cochrane Library, Embase, PubMed, and Web of Science. This meta-analysis included randomized controlled trials (RCTs) and a small number of cohort studies. The differences in mean changes of left ventricular ultrasonic parameters between the treatment and control groups were compared.A total of 31 RCTs and 4 cohort studies involving 4322 patients were analyzed. GLP-1RA was more significantly associated with improvement in left ventricular end-systolic diameter (LVESD) [MD = -0.38 mm, 95% CI (-0.66, -0.10)] and LV mass index (LVMI) [MD = -1.07 g/m2, 95% CI (-1.71, -0.42)], but significantly decreased e' [MD = -0.43 cm/s 95% CI (-0.81, -0.04)]. DPP-4i was more strongly associated with improvement in e' [MD = 3.82 cm/s, 95% CI (2.92,4.7)] and E/e'[MD = -5.97 95% CI (-10.35, -1.59)], but significantly inhibited LV ejection fraction (LVEF) [MD = -0.89% 95% CI (-1.76, -0.03)]. SGLT-2i significantly improved LVMI [MD = -0.28 g/m2, 95% CI (-0.43, -0.12)] and LV end-diastolic diameter (LVEDD) [MD = -0.72 ml, 95% CI (-1.30, -0.14)] in the overall population, as well as E/e' and SBP in T2DM patients combined with CVD, without showing any negative effect on left ventricular function.The results of the network meta-analysis provided high certainty to suggest that SGLT-2i may be more effective in cardiac remodeling compared to GLP-1RA and DPP-4i. While GLP-1RA and DPP-4i may have a tendency to improve cardiac systolic and diastolic function respectively. SGLT-2i is the most recommended drug for reversing ventricular remodeling in this meta-analysis." @default.
• W4380079079 created "2023-06-10" @default.
• W4380079079 creator A5002194502 @default.
• W4380079079 creator A5017682835 @default.
• W4380079079 creator A5035282947 @default.
• W4380079079 creator A5035381007 @default.
• W4380079079 creator A5066713555 @default.
• W4380079079 creator A5068088670 @default.
• W4380079079 creator A5088021705 @default.
• W4380079079 creator A5089666788 @default.
• W4380079079 date "2023-06-09" @default.
• W4380079079 modified "2023-09-23" @default.
• W4380079079 title "Effects of new hypoglycemic drugs on cardiac remodeling: a systematic review and network meta-analysis" @default.
• W4380079079 cites W1608068076 @default.
• W4380079079 cites W1971978582 @default.
• W4380079079 cites W2064130493 @default.
• W4380079079 cites W2065270910 @default.
• W4380079079 cites W2120822075 @default.
• W4380079079 cites W2127854619 @default.
• W4380079079 cites W2131490500 @default.
• W4380079079 cites W2142830692 @default.
• W4380079079 cites W2146264128 @default.
• W4380079079 cites W2150959326 @default.
• W4380079079 cites W2181968881 @default.
• W4380079079 cites W2214416180 @default.
• W4380079079 cites W2335779504 @default.
• W4380079079 cites W2340884845 @default.
• W4380079079 cites W2510276698 @default.
• W4380079079 cites W2567362164 @default.
• W4380079079 cites W2613213879 @default.
• W4380079079 cites W2766765254 @default.
• W4380079079 cites W2774743973 @default.
• W4380079079 cites W2803581246 @default.
• W4380079079 cites W2806521060 @default.
• W4380079079 cites W2897826217 @default.
• W4380079079 cites W2900413769 @default.
• W4380079079 cites W2920321379 @default.
• W4380079079 cites W3008930226 @default.
• W4380079079 cites W3011587204 @default.
• W4380079079 cites W3015179476 @default.
• W4380079079 cites W3037876601 @default.
• W4380079079 cites W3043214131 @default.
• W4380079079 cites W3102766101 @default.
• W4380079079 cites W3107307985 @default.
• W4380079079 cites W3121027668 @default.
• W4380079079 cites W3128624487 @default.
• W4380079079 cites W3140265053 @default.
• W4380079079 cites W3184399299 @default.
• W4380079079 cites W3186623796 @default.
• W4380079079 cites W3207455921 @default.
• W4380079079 cites W4200026682 @default.
• W4380079079 cites W4206183782 @default.
• W4380079079 cites W4214740800 @default.
• W4380079079 cites W4223515927 @default.
• W4380079079 cites W4225728142 @default.
• W4380079079 cites W4281400813 @default.
• W4380079079 cites W4286268477 @default.
• W4380079079 cites W4289653959 @default.
• W4380079079 cites W4323652415 @default.
• W4380079079 doi "https://doi.org/10.1186/s12872-023-03324-6" @default.
• W4380079079 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/37296380" @default.
• W4380079079 hasPublicationYear "2023" @default.
• W4380079079 type Work @default.
• W4380079079 citedByCount "0" @default.
• W4380079079 crossrefType "journal-article" @default.
• W4380079079 hasAuthorship W4380079079A5002194502 @default.
• W4380079079 hasAuthorship W4380079079A5017682835 @default.
• W4380079079 hasAuthorship W4380079079A5035282947 @default.
• W4380079079 hasAuthorship W4380079079A5035381007 @default.
• W4380079079 hasAuthorship W4380079079A5066713555 @default.
• W4380079079 hasAuthorship W4380079079A5068088670 @default.
• W4380079079 hasAuthorship W4380079079A5088021705 @default.
• W4380079079 hasAuthorship W4380079079A5089666788 @default.
• W4380079079 hasBestOaLocation W43800790791 @default.
• W4380079079 hasConcept C126322002 @default.
• W4380079079 hasConcept C134018914 @default.
• W4380079079 hasConcept C164705383 @default.
• W4380079079 hasConcept C2776478404 @default.
• W4380079079 hasConcept C2777180221 @default.
• W4380079079 hasConcept C2778763485 @default.
• W4380079079 hasConcept C2781308992 @default.
• W4380079079 hasConcept C2910068830 @default.
• W4380079079 hasConcept C555175668 @default.
• W4380079079 hasConcept C555293320 @default.
• W4380079079 hasConcept C71924100 @default.
• W4380079079 hasConcept C95190672 @default.
• W4380079079 hasConceptScore W4380079079C126322002 @default.
• W4380079079 hasConceptScore W4380079079C134018914 @default.
• W4380079079 hasConceptScore W4380079079C164705383 @default.
• W4380079079 hasConceptScore W4380079079C2776478404 @default.
• W4380079079 hasConceptScore W4380079079C2777180221 @default.
• W4380079079 hasConceptScore W4380079079C2778763485 @default.
• W4380079079 hasConceptScore W4380079079C2781308992 @default.
• W4380079079 hasConceptScore W4380079079C2910068830 @default.
• W4380079079 hasConceptScore W4380079079C555175668 @default.
• W4380079079 hasConceptScore W4380079079C555293320 @default.
• W4380079079 hasConceptScore W4380079079C71924100 @default.
• W4380079079 hasConceptScore W4380079079C95190672 @default.
• W4380079079 hasFunder F4320327891 @default.
• W4380079079 hasIssue "1" @default.

• next